While in RARS-T, JAK2V617F mutation is common and associated with good prognosis, the clinical and prognostic impact of this mutation in other MDS is unknown. We collected data from 132 non-RARS-T MDS with known JAK2V617F mutation status. JAK2V617F mutation was significantly correlated with lower progression to AML ( p<.0011) and better overall survival (OS, p=011). OS difference persisted after matching on age, sex, IPSS and % marrow blast ( p=031). Thus, in MDS other than RARS-T, JAK2V617F mutation may be associated with favorable outcome. © 2013 The Authors.
de Renzis, B., Mansat-De Mas, V., Wattel, E., Beyne-Rauzy, O., Knoops, L., Cabrespine, A., … Fenaux, P. (2013). Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study. Leukemia Research Reports, 2(2), 64–66. https://doi.org/10.1016/j.lrr.2013.06.003